[Clinical efficacies of antifungal injections].
The incidence of fungal infection is increasing. Amphotericin B has been the gold standard in antifungal chemotherapy for a long time. Within the past few years, three novel antifungal agents have been approved to evaluate the clinical benefits in Japan. Liposomal amphotericin B is developed to reduce toxicities of amphotericin B. Voriconazole, a kind of the new broad-spectrum triazoles, is recommended for the primary treatment of invasive aspergillosis. Micafungin is a new lipopeptide antifungal agent of the echinocandin class. These drugs might provide an individualized and more effective antifungal therapy for each patient. On the other hand, we need to establish a new standard therapy.